Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) is projected to post its Q2 26/27 results before the market opens on Friday, October 23rd. Analysts expect the company to post earnings of $0.0951 per share and revenue of $892.16 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 26/27 earnings results page for the latest details on the call scheduled for Friday, October 23, 2026 at 10:00 AM ET.
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a net margin of 10.15% and a return on equity of 9.49%. The business had revenue of $850.26 million during the quarter, compared to the consensus estimate of $850.56 million. On average, analysts expect Dr. Reddy’s Laboratories to post $0.45 EPS for the current fiscal year and $0.57 EPS for the next fiscal year.
Dr. Reddy’s Laboratories Stock Performance
RDY opened at $13.19 on Thursday. Dr. Reddy’s Laboratories has a 12-month low of $11.36 and a 12-month high of $15.67. The stock has a market cap of $11.01 billion, a price-to-earnings ratio of 29.97, a PEG ratio of 2.76 and a beta of 0.29. The business has a 50 day moving average of $12.32 and a 200-day moving average of $12.91. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.03.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Citigroup raised Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and boosted their target price for the stock from $1,040.00 to $1,450.00 in a report on Tuesday, September 29th. Weiss Ratings downgraded Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, October 17th. Finally, BNP Paribas Exane raised shares of Dr. Reddy’s Laboratories to an “outperform” rating and set a $14.80 price objective for the company in a research report on Monday, October 12th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Hold” and a consensus price target of $732.40.
View Our Latest Stock Analysis on Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible.
Its business includes generic prescription drugs, active pharmaceutical ingredients, biosimilars, specialty products and over-the-counter consumer healthcare products. Dr. Reddy’s offers medicines across therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology.
The company serves patients and healthcare providers in India, the United States, Europe and a range of other international markets, including emerging markets.
Read More
- Five stocks we like better than Dr. Reddy’s Laboratories
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
